| abstract |
The present disclosure relates to tricyclic compounds, preparation processes and pharmaceutical compositions containing them. Specifically, the present disclosure relates to novel tricyclic compounds presented by formula (I), preparation processes and pharmaceutical compositions containing the same, and their use as a therapeutic agent, especially use as GPR119 agonists and the use as drugs for treatment treating diabetes and metabolic syndrome diseases in which each substitute group of general formula (I) is as defined in the specification. |